Coronavirus: WHO chief urges end to 'politicisation' of virus | WeForNews | Latest News, Blogs Coronavirus: WHO chief urges end to ‘politicisation’ of virus – WeForNews | Latest News, Blogs
Connect with us

Disaster

Coronavirus: WHO chief urges end to ‘politicisation’ of virus

An advisor to the WHO chief earlier said that their close work with China had been “absolutely essential” in understanding the disease in its early stages.

Published

on

Tedros Adhanom Ghebreyesus WHO

The head of the World Health Organization (WHO) has urged unity, a day after the agency came under fire from US President Donald Trump.

Speaking on Wednesday, Director-General Tedros Adhanom Ghebreyesus defended the WHO’s work and called for an end to the politicisation of Covid-19.

Mr Trump said Tuesday he would consider ending US funding for the agency.

The president accused the WHO of being “very China-centric” and said they “really blew” their pandemic response.

Dr Tedros has now dismissed the comments, insisting: “We are close to every nation, we are colour-blind.”

Covid-19 first emerged last December in the Chinese city of Wuhan, which has just ended an 11-week lockdown.

An advisor to the WHO chief earlier said that their close work with China had been “absolutely essential” in understanding the disease in its early stages.

Read: Trump threatens to stop WHO funding as NY deaths pass 9/11 fatalities

Mr Trump’s comments came in the context of criticism of his own administration’s handling of the pandemic.

Cities

Mamata to introduce Covid management system in Bengal

He said that at present the state has over 50,000 active Covid-19 cases and 87.6 percent of the coronavirus deaths were caused due to co-morbidities.

Published

on

Mamata Banerjee

Kolkata, Aug 6 : The Mamata Banerjee-led West Bengal government is putting in place a comprehensive Covid management system to handle the spike in coronavirus patients in the state.

State chief secretary Rajiv Sinha said that there are enough beds in Kolkata and other districts, adding that 3,000 Covid-19 patients are currently undergoing treatment in various hospitals.

“We are putting in place a Covid management system in the state. Every evening at 9 p.m. all state government-run hospitals and private medical facilities will update the number of their critical patients, mild and asymptomatic patients. The statistics will be made available in the public domain so that anyone can get to know the details,” Sinha told reporters at the state secretariat.

He said that people would get to know all the relevant details about the saturation levels, the present situation, gender of the patient, age and other health related information by just clicking on the website.

“Covid patients can also call up on the direct telemedicine number 033-23576001 for any medical help. A five-member team of medical experts has been constituted with a senior biologist who will visit testing labs and verify if testing is legitimate or not,” Sinha said.

He said that at present the state has over 50,000 active Covid-19 cases and 87.6 percent of the coronavirus deaths were caused due to co-morbidities.

Chief minister Mamata Banerjee, who was also present during the media interaction, said that the discharge rate in the state is over 70 percent, which is very good. About 87.6 percent of the deaths are due to co-morbidities. We stated it earlier, now everyone is following the same protocol, she said.

Continue Reading

Disaster

Glenmark announces 400 mg ‘FabiFlu’ for COVID-19 treatment

Published

on

Glenmark Fabiflu

Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral – FabiFlu — for the treatment of mild to moderate COVID-19 in India.

It was the first Indian company to commercially launch an antiviral drug – Favipiravir with brand name FabiFlu – for the treatment COVID-19 patients. The company received marketing and manufacturing approval from the Drug Controller General of India and launched the product in the Indian market on June 20.

According to the company, the higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.

Earlier, the 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1, followed by 8 tablets each day thereafter for a maximum of 14 days.

A higher pill burden has been associated with lower adherence to therapy, the latter affecting viral suppression and overall treatment outcomes. Reducing the pill burden has also been a demand from doctors and patients to enable adherence, the company said.

“With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets required on Day 1, and thereafter 2 tablets twice a day from Day 2 till end of the course,” Glenmark Pharmaceuticals added.

Explaining the significance of this development, Monika Tandon, Vice President and Head, Clinical Development of Glenmark Pharmaceuticals Limited said, “The 200 mg dosage of FabiFlu was developed in line with global formulations of the drug Favipiravir, which had similar strength. The 400 mg version is a result of Glenmark’s own R&D efforts to improve treatment experience for patients in India.”

She added, “Being the first company to launch Favipiravir in India, we continue to innovate and seek new treatment options for Covid-19 patients. Introducing this higher strength of FabiFlu is in line with these efforts to ensure a smoother experience for patients, by reducing their daily pill burden.”

Glenmark has also commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral Favipiravir, as part of an open label, multicentre, single arm study.

It is also conducting another Phase III clinical trial to evaluate the efficacy of two antiviral drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult Covid-19 patients in India.

The combination study which is called the FAITH trial is looking to enrol 158 hospitalized patients of moderate Covid-19 in India. Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, facilitating early clinical cure and discharge of patients.

Continue Reading

Disaster

As India inches towards 2 million cases, Harsh Vardhan says, coronavirus spread contained in country

Speaking at a virtual meeting of WHO’s Regional Director, South East Asia, with Health Ministers from the region, the health minister also alluded to efficacy of the govt’s containment strategy

Published

on

By

Harsh Vardhan

India’s Health Minister Harsh Vardhan on Thursday asserted that the spread of coronavirus has been contained in the country, citing how half the total cases are from three states only and another 30 per cent from seven others.

His remarks come as the country is inching towards the grim mark of two million cases. It has already logged over 40,000 deaths and is recording more than 50,000 daily cases since the past few days.

Speaking at a virtual meeting of WHO’s Regional Director, South East Asia, Poonam Khetrapal Singh with Health Ministers from the region on maintaining essential health services and public health programmes in the context of the Covid-19 pandemic, Harsh Vardhan alluded to the efficacy of the government’s containment strategy.

“The strategy has been successful in that 50 per cent of the cases are from three states and 32 per cent of the rest are from seven states. The spread of the virus thus has been contained.”

The Minister said that the lockdown was effective in slowing down the rate of growth of cases and gave the government time to augment the health infrastructure and testing facilities.

“From one lab in January, India has 1,370 labs today. Indians anywhere can access a lab within three hours travel time. 33 of the 36 states and UTs (Union Territories) exceed WHO’s recommendation of testing 140 people per million per day.”

Harsh Vardhan also said that the country was “preparing for the pandemic as soon as China informed the World Health Organisation on January 7”, over three weeks before the first case emerged.

India had reported its first coronavirus case on January 30 when a student from Kerala, who was studying in China’s Wuhan University, came back to India and tested positive for the deadly virus.

Harsh Vardhan also stressed that earlier viral outbreaks like the Avian Influenza, H1N1, Zika and Nipah had provided institutional memory in designing containment and management strategies.

“India’s proactive and graded multi-level institutional response to Covid-19 made it possible to have very low cases per million and deaths per million in spite of having a high population density, and low fractional GDP spending, per capita doctor, and hospital bed availability as compared to other developed countries,” he contended.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.